medigraphic.com
Órgano Oficial de la Asociación Mexicana de Infectología Pediátrica y la SLIPE.

2005, Number 72

<< Back Next >>

Rev Enfer Infec Pediatr 2005; 18.19 (72)

Linezolid IV/VO effectiveness and safety vs. Vancomicin IV in Gram positive bacterial infection treatment in children

Coria LJJ, Gadea ÁT, Gómez BD

Language: Spanish
References: 27
Page: 97-104
PDF size: 132.86 Kb.


ABSTRACT

Introduction. Gram-Positive bacterial infections are common causes of both nosocomial and community-adquired illnesses. Linezolid has shown in vitro and in vivo activity against these pathogens.
Objective. To evaluate the efficacy, safety, and acceptance of Linezolid IV and VO, compared with vancomycin IV in suspected or confirmed Gram-positive bacterial infectious in children.
Material and Methods. From October to December 2001 a randomized, opened, comparative clinical trial was made, in children of 3 months to 11 years of age, hospitalized with suspicion or confirmed infection by Gram-positive bacteria. Two groups were formed: those who received Linezolid IV/VO and those that received Vancomicina IV. Treatment duration was 10 - 14 days with follow up until 49 days. The patients were followed with: CBC, blood chemistry and cultures of the affected areas on admission and 3rd, 10th day, at end of treatment, and then on the 12th or 28th day post last dose.
Results. We analyzed 16 patients, 8 in each group, the diagnoses were: sepsis, pneumonia and skin and soft tissue infection. Staphylococcus coagulase negative was isolated in 18.8% of cases. The rate of clinical answer to treatment in each group was similar (p = 1.00). Microbiological eradication was 100% for Linezolid and 75% for Vancomicina, p = 1.00. The patients that were changed to Linezolid VO on the third day, showed a reduction in hospital stay of 5 days versus 13 that received only IV treatment.
Conclusions. Linezolid as effective, both clinic and microbiologically, as vancomycin in the treatment of Gram-positive bacterial infections, it offers a better acceptance, because it has the advantage to be used orally.


REFERENCES

  1. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother. 1992;29 SA:19-24.

  2. Center for Control and Prevention Diseases. National Nosocomial Infections Surveillance (NNIS) System Report, data summary for October 1986 – April 1998. Issued June 1998: A report from the NNIS System. Hospital Infections Program, National center for Infectious Diseases, U.S. Public Health Services, U:S. Department of Health and Human Services, Atlanta, Georgia.

  3. Bartlett JG, Hospital- Acquired Pneumonia. In: Pine JE (ed). Management of Respiratory Tract Infections. Baltimore, MD. Williams & Wilkins. 1997:56-70.

  4. Blinkhorn RJ. Hospital-Acquired Pneumonia. In: Baum GL, Crapo JD, Celli BR, Karlinsky JB (eds). Text Book of Pulmonary Disease. 6th ed, Philadelphia, PA, Lippincott-Raven Publisher.1998:543-60.

  5. Tunnessen WW. A survey of Skin Disorders Seen in Pediatric General and Dermatology Clinics. Pediatric Dermatology.1984;1:219-22.

  6. Tack KL, Keyserling CH, McCarty J, Hedrick JA, et al. Study of Use of Cefnidir versus Cephalexin for treatment od Skin Infections in Pediatric Patients. Antimicrob Agents Chemother. 1997;57:739-42.

  7. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT & Braveny I. Methicillin resistant Staphylococcus aureus in Europe. Euro J Clin Microb Infect Dis. 1994;13:50-5.

  8. Waldvogel FA. Staphylococcus aureus (including toxic shock syndrome). In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 4th ed. New York, Churchill Livingstone, USA. 1995:1754-77.

  9. Herol BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, et al. Community-Acquired Staphylococcus aureus resistant to methicillin in Children with no Identified Predisposing Risk. JAMA.1998;279:593-98.

  10. Dunkle LM, Naqvi SH, McCallum R, Lofgren JP. Eradication of epidemic methicillin-gentamicin-resistant Staphylococcus aureus in an intensive care nursery. Am J Med.1981;70:455-58.

  11. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AS & Kusne. Differences in outcome of patients with bacteremia due to vancomycin-resistan Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis.1996;22:663-70.

  12. Newwll KA, Millis JM, Arnow PM, Bruce DE, Woodle ES, Cronin DC, et al. Incidence and outcome of infections by vancomycin-resistant Enterococcus following orthoptic liver transplantation. Transplantation. 1998;65:439-42.

  13. Lin AH, Murray RW, Vidmar TJ, Marotti KR. Oxazolidinone eperezolid binds at the 50S ribosomal subunit and competes with the binding of chloramphenicol and lincomycin. Antimicrob Agent Chemother. 1997;41:2127-31.

  14. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of oxazolidinonas-effects of Linezolide and eperzolid on translation reactions. Antimicrob Agent Chemother.1997;41:2132-36.

  15. Swaney SM, Aoki H, Ganoza MC, et al. The oxazolidinone Linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother.1998;42:3251-5.

  16. Drori-Zeides T, Raver D, Schelsinger Y, M.Yinnon A. Practical Guidelines for Vancomycin Usage, With Prospective Drug-Utilization Evaluation. Infect Control Hosp Epidem. 2000:21(1):45-47.

  17. Zurenco G, Yagi B, Chaadt R, et al. In vitro activities of U-100592, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996;40:839-45.

  18. Fresser L, Rybak M. The pharmacologic and bacteriologic properties of ozaxolidinones, a new class of synthetic antimicrobials. Pharcacotherapy. 1998;18:456-62.

  19. Fagon J, Patrick H, Haa D. Treatment of Gram-positive nosocomial pneumonia: prospective, randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Resp Crit Care Med. 2000;161:753-62.

  20. Kaplan ShL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J. 2003;22:677-85.

  21. Cammarata S, San Pedro G, Timm J. Comparison of Linezolid versus ceftrixone/cefpodoxime in the treatment of hospitalized patients with communithy-acquired pneumonia. Poster 237 of European Society Microbiology of Infectious Disease. 2000.

  22. Duval S, Seas C, Bruss J, Mc Connell M, Todd. Comparison of Linezolid tooral claritromycin in the treatmen of uncomplicated skin infections: results from a multinational phase III trial. Abstract of the 9th International Congress on Infectious Disease. 2000:181.

  23. Rubinstein E, Cammarata K, Oliphant T, Wunderrink R. Linezolid (PNU-100766) versus vancomycin in the treatment of Hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter Study. Clin Infect Dis. 2001;32:402-12.

  24. Kaplan ShL, Patterson L, Edwards KM, Azimi PH, Bradley JS, Blumer JL et al.Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr Infect Dis J. 2001;20:488-94.

  25. Montecalvo MA, Shay DK, Patel P, Tacsa L, Maloney SA, Jarvis WR & Wormser GP. Bloodstream infections with vancomycin-resistant enterococci. Arch Inter Med.1996;1561:458-62.

  26. Miller D, Urdaneta V, Weltman A, Park S. Vancomycin-resistant Staphylococcus aureus: Pennsylvania,2002. MMWR.2002;51:902.

  27. Smith TL, Pearson ML, Wicox KR, et al. Emergence of of vancomycin resistance in Staphylococcus aureus. N Engl J Med.1999;340:493-501.




2020     |     www.medigraphic.com